TENAX THERAPEUTICS, INC.

TENXReported to SECin USCIK 0000034956Filings at SEC EDGAR

No score on this page, by design. Everything here is a fact from a public U.S. register: insider filings at the SEC (Form 4), lobbying filings under the Lobbying Disclosure Act, trades reported by members of Congress under the STOCK Act, and fund holdings in 13F filings. Our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.

This page is free to read, and it stops after 5 rows. Those are the 5 most recent Form 4 lines at this company, out of 15. Reading the whole list, and the full version of each filer's page, is part of the subscription. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.

The most recent filings

Most recent filing first: every line of every Form 4 at this company that passed our review, the same lines as on the register. Reported is the day the filing reached the SEC, usually within two business days of the trade. Amounts are in U.S. dollars, as the form states them.

5 of 15
Form 4 lines at TENAX THERAPEUTICS, INC., most recent filing first
Filed byTypeValueReportedFiled byValueTypeSharesReported
Doogan Declan—Open-market buy$101,76053,000 sharesSep 17, 2026Doogan Declan$101,760Buy · Sep 17Open-market buy53,000Sep 17, 2026
Giordano Christopher ThomasCEOOpen-market buy$8,8374,850 sharesSep 15, 2026Giordano Christopher ThomasCEO$8,837Buy · Sep 15Open-market buy4,850Sep 15, 2026
Giordano Christopher ThomasCEOOpen-market buy$11,2506,000 sharesSep 15, 2026Giordano Christopher ThomasCEO$11,250Buy · Sep 15Open-market buy6,000Sep 15, 2026
STAAB THOMAS R IIChief Financial OfficerOpen-market buy$10,9815,675 sharesSep 15, 2026STAAB THOMAS R IIChief Financial Officer$10,981Buy · Sep 15Open-market buy5,675Sep 15, 2026
ADAR1 Capital Management, LLC—Open-market buy$1,604,160900,000 sharesSep 8, 2026ADAR1 Capital Management, LLC$1,604,160Buy · Sep 8Open-market buy900,000Sep 8, 2026